Agilent Technologies, Inc. A
We take great care to ensure that the data presented and summarized in this overview for AGILENT TECHNOLOGIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding A
View all-
Vanguard Group Inc Valley Forge, PA33.4MShares$4.3 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY25.3MShares$3.25 Billion0.08% of portfolio
-
Massachusetts Financial Services CO Boston, MA15.6MShares$2 Billion0.72% of portfolio
-
State Street Corp Boston, MA12.8MShares$1.65 Billion0.08% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$1.19 Billion0.25% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.24MShares$1.06 Billion0.74% of portfolio
-
Geode Capital Management, LLC Boston, MA6.95MShares$893 Million0.09% of portfolio
-
Pictet Asset Management Sa Geneva 73, V86.64MShares$854 Million0.96% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V85.17MShares$664 Million0.87% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M4.4MShares$565 Million0.27% of portfolio
Latest Institutional Activity in A
Top Purchases
Top Sells
About A
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Insider Transactions at A
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 15
2024
|
Angelica Riemann Senior Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
172
-1.12%
|
$21,844
$127.07 P/Share
|
Nov 15
2024
|
Rodney Gonsalves V.P., Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
276
-1.28%
|
$35,052
$127.07 P/Share
|
Nov 15
2024
|
Padraig Mcdonnell President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
715
-2.97%
|
$90,805
$127.07 P/Share
|
Nov 15
2024
|
Robert W. Mc Mahon Sr. VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,295
-0.8%
|
$164,465
$127.07 P/Share
|
Nov 15
2024
|
Henrik Ancher Jensen Sr Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
796
-0.96%
|
$101,092
$127.07 P/Share
|
Sep 27
2024
|
Padraig Mcdonnell President and CEO |
SELL
Open market or private sale
|
Direct |
47
-0.19%
|
$7,050
$150.0 P/Share
|
Sep 26
2024
|
Dominique Grau Senior Vice President |
SELL
Open market or private sale
|
Indirect |
5,010
-9.68%
|
$726,450
$145.0 P/Share
|
Sep 26
2024
|
Dominique Grau Senior Vice President |
SELL
Open market or private sale
|
Direct |
9,990
-19.98%
|
$1,448,550
$145.0 P/Share
|
Aug 22
2024
|
Padraig Mcdonnell President and CEO |
SELL
Open market or private sale
|
Direct |
1,958
-7.51%
|
$283,910
$145.0 P/Share
|
Jul 26
2024
|
Padraig Mcdonnell President and CEO |
SELL
Open market or private sale
|
Direct |
1,958
-6.98%
|
$274,120
$140.0 P/Share
|
Jul 02
2024
|
Bret Di Marco Senior Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
1,618
+50.0%
|
$202,250
$125.78 P/Share
|
Jun 18
2024
|
Padraig Mcdonnell President and CEO |
SELL
Open market or private sale
|
Direct |
1,958
-6.53%
|
$264,330
$135.0 P/Share
|
Jun 10
2024
|
Dominique Grau Senior Vice President |
SELL
Open market or private sale
|
Direct |
15,000
-23.26%
|
$1,995,000
$133.28 P/Share
|
Jun 05
2024
|
Dominique Grau Senior Vice President |
BUY
Bona fide gift
|
Indirect |
515
+0.97%
|
$68,495
$133.56 P/Share
|
Jun 05
2024
|
Dominique Grau Senior Vice President |
SELL
Bona fide gift
|
Direct |
515
-0.79%
|
$68,495
$133.56 P/Share
|
Jun 03
2024
|
Padraig Mcdonnell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,807
+13.81%
|
$629,717
$131.4 P/Share
|
Jun 03
2024
|
Padraig Mcdonnell President and CEO |
SELL
Open market or private sale
|
Direct |
1,958
-7.21%
|
$254,540
$130.0 P/Share
|
May 29
2024
|
George A Scangos Director |
BUY
Bona fide gift
|
Indirect |
3,443
+16.14%
|
$499,235
$145.48 P/Share
|
May 29
2024
|
George A Scangos Director |
SELL
Bona fide gift
|
Direct |
3,443
-15.64%
|
$499,235
$145.48 P/Share
|
May 17
2024
|
Padraig Mcdonnell President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-0.64%
|
$26,796
$154.23 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 151K shares |
---|---|
Exercise of conversion of derivative security | 76.9K shares |
Bona fide gift | 3.96K shares |
Payment of exercise price or tax liability | 4.09K shares |
---|---|
Open market or private sale | 195K shares |
Bona fide gift | 3.96K shares |